Francis R. LeBlanc

Francis R. LeBlanc

Auto-generated profile, based on publicly available information

Francis R. LeBlanc

Division of Oncology, Cancer and Blood Diseases Institute Cincinnati Children's Hospital Medical Centre Cincinnati Ohio USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2010 in Hepatology
Verified
Journal Article
Open access
PDF file
WDWei Ding
Wei Ding
HYHanning You
Hanning You
HDHien Dang
Hien Dang
FLFrancis LeBlanc
Francis LeBlanc
VGVivian Galicia
Vivian Galicia
BRBart C. Rountree
Bart C. Rountree
Epithelial-to-mesenchymal transition (EMT) is predicted to play a critical role in metastatic disease in hepatocellular carcinoma. In this study, we used a novel murine model of EMT to elucidate a mechanism of tumor progression and metastasis. A total of 2 × 106 liver cells isolated from Pten loxp/loxp/ Alb-Cre + mice, expanded from a single CD133+CD45− cell clone, passage 0 (P0), were sequentially transplanted to obtain two passages of tumor cells, P1 and P2. Cells were analyzed for gene expression using microarray and real-time polymerase chain reaction. Functional analysis included cell proliferation, migration, and invasion in vitro and orthotopic tumor metastasis assays in vivo. Although P0, P1, and P2 each formed tumors consistent with mixed liver epithelium, within the P2 cells, two distinct cell types were clearly visible: cells with epithelial morphology similar to P0 cells and cells with fibroblastoid morphology. These P2 mesenchymal cells demonstrated increased locomotion on wound healing; increased cell invasion on Matrigel basement membrane; increased EMT-associated gene expression of Snail1 , Zeb1 , and Zeb2 ; and down-regulated E-cadherin . P2 mesenchymal cells demonstrated significantly faster tumor growth in vivo compared with P2 epithelial counterparts, with invasion of intestine, pancreas, spleen, and lymph nodes. Furthermore, P2 mesenchymal cells secreted high levels of hepatocyte growth factor (HGF), which we propose acts in a paracrine fashion to drive epithelial cells to undergo EMT. In addition, a second murine liver cancer stem cell line with methionine adenosyltransferase 1a deficiency acquired EMT after sequential transplantations, indicating that EMT was not restricted to Pten-deleted tumors. Conclusion: EMT is associated with a high rate of liver tumor proliferation, invasion, and metastasis in vivo, which is driven by HGF secreted from mesenchymal tumor cells in a feed-forward mechanism.

1 May 2014 in Blood Reviews
Verified
Journal Article
Closed access
SSSteven Nathaniel Steinway
Steven Nathaniel Steinway
FLFrancis LeBlanc
Francis LeBlanc
TLThomas P. Loughran
Thomas P. Loughran

5 August 2014 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
EPE. Poullot
E. Poullot
RZR. Zambello
R. Zambello
FLF. Leblanc
F. Leblanc
BBB. Bareau
B. Bareau
EME. De March
E. De March
TLT. Lamy
T. Lamy
The 2008 World Health Organization (WHO) classification distinguishes three entities among the large granular lymphocytic leukemia (LGL leukemia): T-cell LGL leukemia (T-LGL leukemia), aggressive natural killer (NK) cell leukemia, and chronic NK lymphoproliferative disorders (LPD), the later considered as a provisional entity. Only a few and small cohorts of chronic NK LPD have been published. We report here clinicobiological features collected retrospectively from 70 cases of chronic NK LPD, and compared with those of T-LGL leukemia. There were no statistical differences between chronic NK LPD and T-LGL leukemia concerning median age [61 years (range 23–82 years)], organomegaly (26%), associated autoimmune diseases (24%), and associated hematological malignancies (11%). Patients with chronic NK LPD were significantly less symptomatic (49% versus 18%, P < 0.001) and the association with rheumatoid arthritis was more rarely observed (7% versus 17%, P = 0.03). The neutropenia (<0.5 × 109/l) was less severe in chronic NK LPD (33% versus 61%, P < 0.001) without difference in the rate of recurrent infections. STAT3 mutation was detected in 12% of the cohort, which is lower than the frequency observed in T-LGL leukemia. Thirty-seven percent of the patients required specific therapy. Good results were obtained with cyclophosphamide. Overall and complete response rates were, respectively, 69% and 56%. Overall survival was 94% at 5 years. This study suggests very high similarities between chronic NK LPD and T-LGL leukemias. Since chronic NK LPD is still a provisional entity, our findings should be helpful when considering further revisions of the WHO classification.

26 April 2018 in Blood
Verified
Journal Article
Open access
PDF file
JYJun Yang
Jun Yang
FLFrancis R. LeBlanc
Francis R. LeBlanc
SDShubha A. Dighe
Shubha A. Dighe
CHCait E. Hamele
Cait E. Hamele
TOThomas L. Olson
Thomas L. Olson
TLThomas P. Loughran
Thomas P. Loughran
Key Points: TRAIL is upregulated in LGL leukemia and TRAIL-DcR2 signaling drives constitutive activation of NF-κB. Proteasome inhibitors (bortezomib and ixazomib) effectively interrupt TRAIL-induced activation of NF-κB and induce apoptosis.

25 July 2012 in Future Oncology
Verified
Journal Article
Closed access
FLFrancis LeBlanc
Francis LeBlanc
DZDan Zhang
Dan Zhang
XLXin Liu
Xin Liu
TLThomas P Loughran
Thomas P Loughran
Large granular lymphocyte (LGL) leukemia is a clonal lymphoproliferative disorder of cytotoxic lymphocytes characterized by an expansion of CD3+ cytotoxic T lymphocytes or CD3- natural killer cells. Patients present with various cytopenias including neutropenia, anemia and thrombocytopenia. In addition, there is an association of T-cell large granular lymphocytic leukemia with rheumatoid arthritis. It is believed that LGL leukemia begins as an antigen-driven immune response with subsequent constitutive activation of cytotoxic T lymphocytes or natural killer cells through PDGF and IL-15 contributing to their survival. Consequently, this leads to a dysregulation of apoptosis and dysfunction of the activation-induced cell death pathway. Treatment of LGL leukemia is based on a low-dose immunosuppressive regimen using methotrexate or cyclophosphamide. However, no standard of therapy has been established, as large prospective trials have not been conducted. In addition, some patients are refractory to treatment...

7 August 2015 in Cancer Biology & Therapy
Verified
Journal Article
Open access
FLFrancis R LeBlanc
Francis R LeBlanc
XLXin Liu
Xin Liu
JHJeremy Hengst
Jeremy Hengst
TFTodd Fox
Todd Fox
VCValerie Calvert
Valerie Calvert
TLThomas P Loughran
Thomas P Loughran
Sphingolipid metabolism has been identified as a potential therapeutic target in cancer. Sphingosine-1-phosphate (S1P) is a potent bioactive sphingolipid metabolite produced by sphingosine kinases-1 and −2 (SPHK1 and SPHK2). Elevated SPHK1 has been found in numerous cancer types and been shown to contribute to survival, chemotherapeutic resistance and malignancy. However, its role in large granular Natural Killer (NK) large granular lymphocyte (LGL) leukemia has not been investigated. Here, we examine SPHK1 as a therapeutic target in LGL leukemia. We found that SPHK1 is overexpressed in peripheral blood mononuclear cells (PBMCs) from LGL leukemia patients which results in elevated S1P in the sera. The use of SPHK1 inhibitors, SKI-II or SKI-178, decreased leukemic NK cell viability and induced caspase-dependent apoptosis. SKI-II and SKI-178 restored the sphingolipid balance by increasing ceramide and decreasing S1P in leukemic NKL cells. SKI-II and SKI-178 also induced apoptosis in primary NK-LGLs from leukemia patients. Mechanistic studies in NK-LGL cell lines demonstrated that SKI-178 and SKI-II induced cell cycle arrest at G2/M. We found that SKI-178 induced phosphorylation of Bcl-2 at Ser70, and that this was dependent on CDK1. We further show that SPHK1 inhibition with SKI-178 leads to decreased JAK-STAT signaling. Our data demonstrate that SPHK1 represents a novel therapeutic target for the treatment of NK-LGL leukemia.